We lead with love. We innovate with empathy, trust, and respect. Creating space for diverse perspectives and better decisions. By lifting others and doing what's right, we unlock the full potential of our team.
A team deeply experienced in neuroscience, drug development, and the technology that brings them together.
Dr. Desai is the Founder and Chief Executive Officer of Lotus Neuro, where he is building a new category of brain-targeted therapeutics that pair precision focused ultrasound with advanced medicines. A Stanford-trained physician and Biodesign faculty member, he most recently served as Chief Strategic Innovation Officer at Insightec, where he helped build the global focused ultrasound business in neurosurgery — including the market access, medical affairs, and research infrastructure supporting therapeutic delivery across multiple neurologic indications. Before that, he was Global Vice President and Chief Operating Officer at Johnson & Johnson Innovation. The through line of his career: turning breakthrough technology into treatments that reach patients at scale.
Dr. Desai is a frequent contributor to Forbes Healthcare and the Milken Institute and a keynote speaker on the global innovation stage. He has been featured in Life Force, Becker's, CNN, BBC, and Medtech Strategist.
Most importantly, he is the proud father of four children under 15, one Chocolate Labrador, and husband to a much smarter wife.
A neurologist, neuroscientist, and veteran drug developer with a career spanning biopharma, academia, and clinical medicine. He has held senior leadership roles across the industry, including Chief Medical Officer at United Neuroscience, Executive Vice President of Research and Experimental Medicine at Codiak BioSciences, and leadership positions in neurology drug development at Biogen, Novartis, and Merck, where he helped advance programs across neurodegenerative and neurological diseases. Dr. Verma's work focuses on translational neuroscience and precision drug development, with deep expertise in biomarkers, experimental medicine, and early clinical strategy across a wide range of therapeutic modalities. A former U.S. Army Lieutenant Colonel and professor of neurology, he received his MD and PhD from Johns Hopkins University and has dedicated his career to advancing innovative therapies for complex brain disorders.
A bioengineer and leader in genetic medicine innovation, with deep expertise in designing advanced delivery systems for treating complex diseases. She previously served as Vice President and Head of Biogen's Gene Therapy Accelerator Unit and then Head of BioDesign, where she led efforts to develop delivery-enabled transformative therapies for neurodevelopmental, neurodegeneration, and neuromuscular indications. A firm believer in smart public-private partnerships, she served on the founding committee of the FNIH Bespoke Gene Therapy Consortium, bringing together government, non-profit, industry, and academic partners to join forces and bring innovative medicines to patients with ultra-rare diseases. Prior to Biogen, she was a tenured professor at Rice University, where her pioneering work in synthetic virology focused on engineering viruses as programmable platforms for targeted gene delivery. A Fellow of the American Institute for Medical and Biological Engineering, Dr. Suh brings a unique combination of engineering design and ecosystem leadership to advancing next-generation therapeutics.
Three principles shape how we build, partner, and push through the hardest problems in medicine.
We innovate with empathy, trust, and respect. Creating space for diverse perspectives and better decisions. By lifting others and doing what's right, we unlock the full potential of our team.
We treat setbacks as fuel for growth. By taking smart risks, learning fast, and recovering stronger, we turn failure into momentum and better outcomes.
We take full ownership of hard problems and see them through. Accountable and resourceful, we run toward the work others avoid and deliver on it.
Senior advisors lending clinical and scientific depth across neuro-oncology and focused ultrasound.
Graeme is a neurosurgeon and clinician-scientist who serves as Professor and Chair of the Department of Neurosurgery at the University of Maryland School of Medicine and directs its Brain Tumor Program within the Greenebaum Comprehensive Cancer Center. Trained at Johns Hopkins and Cornell, he specializes in neurosurgical oncology, and his research targets the brain-invading tumor cells behind most cancer recurrence. His team is leading the first-in-human U.S. clinical trials of focused ultrasound–mediated blood-brain barrier opening, advancing localized drug-device combination therapies for brain tumors.
Manmeet is a board-certified neuro-oncologist and medical oncologist who serves as Chief Scientific Officer, Chief of Medical Oncology, and Deputy Director at Baptist Health Miami Cancer Institute, where he holds the Fernandez Family Endowed Chair in Cancer Research. A leading expert in primary brain tumors and brain metastases, he previously held the Dean and Diane Miller Family Endowed Chair in Neuro-Oncology at the Cleveland Clinic. An internationally recognized clinical investigator, he has authored more than 200 publications and led numerous multi-site national and international trials advancing new therapies for patients with brain tumors.
Stewardship from leaders across neuroscience, drug development, and company-building.
Maurice is a pioneering medical-technology entrepreneur and CEO of INSIGHTEC, where he is advancing non-invasive, focused-ultrasound therapies. With over two decades of leadership experience, he previously co-founded and led MAKO Surgical, acquired by Stryker for $1.65 billion, and founded Visualization Technology Inc., later acquired by GE Healthcare. Across his career, Dr. Ferré has consistently built and scaled breakthrough platforms that redefine how medicine is delivered.
Scott is a biotech entrepreneur, investor, and strategic advisor with more than two decades of experience building and financing life-sciences companies. He is the founder of The Branta Group, where he has led company formation, capital strategy, and transactions across biotechnology, medical devices, and diagnostics — helping raise over $600 million and supporting numerous IPOs and acquisitions. A venture partner focused on difficult-to-treat cancers such as glioblastoma, he also founded Mission GBM, a global initiative advancing brain-cancer research and care, reflecting his commitment to accelerating innovation and improving patient outcomes.
Lotus is backed by a strategic foundation with a focused investment effort in CNS therapeutics and diagnostics, bringing a long-term view and scale.
We're building a new category in medicine. One that redefines how therapies reach the brain and it takes exceptional people to do it. At Lotus Neuro, you'll work at the intersection of cutting-edge technology, clinical science, and real-world impact, alongside a team deeply experienced in neuroscience, drug development, and innovation.
Whether advancing our platform, partnering with global leaders, or translating breakthroughs into patient outcomes, every role here contributes to changing what's possible in CNS therapy. If you're driven to solve complex problems and want your work to matter at a fundamental level, we'd like to hear from you.
The connective tissue across our preclinical, regulatory, clinical, and partnership workstreams — turning company goals and meeting decisions into tracked, completed work.
A hands-on physician-scientist leader across translational and early clinical development — bridging preclinical science, protocol design, and investigator engagement for our LOFUS-enabled programs from preclinical translation into enrolling trials.
Don't see the right role? We're always glad to meet exceptional people.
Get in touchWhether you're exploring a role, a therapeutics partnership, or a clinical collaboration, we'd love to hear from you.
Your message is on its way to the Lotus Neuro team.
